全文获取类型
收费全文 | 1084篇 |
免费 | 78篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 60篇 |
妇产科学 | 13篇 |
基础医学 | 86篇 |
口腔科学 | 31篇 |
临床医学 | 167篇 |
内科学 | 214篇 |
皮肤病学 | 19篇 |
神经病学 | 29篇 |
特种医学 | 247篇 |
外科学 | 116篇 |
综合类 | 23篇 |
预防医学 | 34篇 |
眼科学 | 52篇 |
药学 | 34篇 |
中国医学 | 5篇 |
肿瘤学 | 35篇 |
出版年
2023年 | 8篇 |
2022年 | 3篇 |
2021年 | 12篇 |
2020年 | 6篇 |
2019年 | 10篇 |
2018年 | 24篇 |
2017年 | 11篇 |
2016年 | 19篇 |
2015年 | 23篇 |
2014年 | 28篇 |
2013年 | 29篇 |
2012年 | 26篇 |
2011年 | 20篇 |
2010年 | 39篇 |
2009年 | 59篇 |
2008年 | 35篇 |
2007年 | 16篇 |
2006年 | 29篇 |
2005年 | 7篇 |
2004年 | 7篇 |
2003年 | 17篇 |
2002年 | 11篇 |
2001年 | 19篇 |
2000年 | 11篇 |
1999年 | 16篇 |
1998年 | 51篇 |
1997年 | 55篇 |
1996年 | 64篇 |
1995年 | 49篇 |
1994年 | 45篇 |
1993年 | 49篇 |
1992年 | 19篇 |
1991年 | 13篇 |
1990年 | 19篇 |
1989年 | 39篇 |
1988年 | 31篇 |
1987年 | 40篇 |
1986年 | 38篇 |
1985年 | 28篇 |
1984年 | 18篇 |
1983年 | 10篇 |
1982年 | 22篇 |
1981年 | 16篇 |
1980年 | 10篇 |
1979年 | 8篇 |
1978年 | 5篇 |
1977年 | 14篇 |
1976年 | 12篇 |
1975年 | 15篇 |
1960年 | 2篇 |
排序方式: 共有1169条查询结果,搜索用时 15 毫秒
1.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
2.
3.
4.
5.
6.
7.
8.
Dr. Schlomo Schneebaum MD Joseph Papo MD Moshe Graif MD Mimi Baratz MD Jack Baron MS Yehuda Skornik MD 《Annals of surgical oncology》1997,4(5):371-376
Background: Despite new adjuvant therapy, 50% of patients with colon cancer will have recurrent disease. This study investigated the
use of a radiolabeled monoclonal antibody in locating occult tumor during surgery for recurrent colorectal cancer.
Methods: Twenty-two patients with recurrent colorectal cancer underwent surgery using the radioimmunoguided surgery (RIGS) system.
All patients were subjected to abdominal and chest computed tomography (CT). Before surgery, patients were injected with the
CC49 monoclonal antibody (MoAb), anti-TAG antibody labeled with125I. Ten patients with elevated carcinoembryonic antigen (CEA) levels and no CT findings had a scintigraphy scan with an anti-CEA
MoAb labeled with99Tc. Human antimouse antibody levels of these patients were within normal limits. Surgical exploration including liver ultrasound
examination was followed by survey with a gamma-detecting probe (GDP).
Results: There was MoAb tumor localization in 100% of the patients. CT found nine tumor sites, traditional surgical exploration 30,
and the GDP 51, with 44 confirmed by pathology (hematoxylin and eosin). The RIGS system found occult tumor in 10 patients
(45.4%) and resulted in major changes in surgical procedure in 11 patients. In the 10 patients who had scintigraphy scans,
10 tumor sites were identified, whereas RIGS found an additional eight sites.
Conclusion: RIGS technology offers a substantial benefit for patients undergoing surgery for recurrent colorectal cancer and a better
chance of finding recurrent tumor intraoperatively in patients who have elevated CEA levels with no other CT findings.
Presented at the Annual Cancer Symposium of The Society of Surgical Oncology, Atlanta, Georgia, March 21–24, 1996. 相似文献
9.
10.